DXCM Share Price

Open 64.51 Change Price %
High 65.76 1 Day 0.58 0.91
Low 63.69 1 Week -3.62 -5.32
Close 64.45 1 Month 2.55 4.12
Volume 892617 1 Year -23.32 -26.57
52 Week High 96.38
52 Week Low 47.92
DXCM Important Levels
Resistance 2 66.37
Resistance 1 65.58
Pivot 64.63
Support 1 63.32
Support 2 62.53
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

DexCom, Inc. (NASDAQ: DXCM)

DXCM Technical Analysis 4
As on 5th Dec 2016 DXCM Share Price closed @ 64.45 and we RECOMMEND Sell for LONG-TERM with Stoploss of 74.58 & Strong Sell for SHORT-TERM with Stoploss of 77.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
DXCM Target for December
1st Target up-side 76.18
2nd Target up-side 83.81
3rd Target up-side 91.44
1st Target down-side 54.4
2nd Target down-side 46.77
3rd Target down-side 39.14
DXCM Other Details
Segment EQ
Market Capital 902109952.00
Sector Healthcare
Industry Medical Instruments & Supplies
Offical website http://www.dexcom.com
DXCM Address
DXCM
6340 Sequence Drive
San Diego, CA 92121
United States
Phone: 858-200-0200
DXCM Latest News
Interactive Technical Analysis Chart DexCom, Inc. ( DXCM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on DexCom, Inc.
DXCM Business Profile
DexCom, Inc. (DexCom) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company had received approval from the United States Food and Drug Administration (FDA) for its third generation system, the SEVEN PLUS, which is designed for up to seven days of continuous use. The SEVEN PLUS is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices. The enabling technologies for the Company�s sensors include biomaterials, membrane systems, electrochemistry and low power microelectronics.